혈액 스크리닝 시장 : 제품, 기술, 최종 용도별 - 세계 예측(2024-2032년)

Blood Screening Market is anticipated to register a CAGR of 7.3% between 2024 and 2032, owing to the advancements in healthcare technologies and increased awareness regarding the importance of early disease detection. Blood screening helps in identifying various medical conditions, including infectious diseases and genetic disorders. As per WHO, a total of 1.3 million people died from tuberculosis in 2022, making it the second leading infectious disease worldwide after COVID-19.

The ongoing efforts to control and prevent infectious outbreaks have led to an increased focus on blood screening as a vital component of public health initiatives. Additionally, the need for blood screening in blood banks and transfusion centers to ensure the safety of blood donations further stimulates market growth.

Blood screening industry is segmented based on product, technology, end-use, and region.

Western blot assay segment is slated to witness significant growth during 2024-2032, owing to the precision and versatility in detecting specific proteins within blood samples. This technique offers high sensitivity and accuracy, making it particularly effective in identifying various antibodies, antigens, or specific proteins associated with infectious diseases or other medical conditions. It provides detailed information about the presence and concentration of target molecules in a blood sample, making it an invaluable tool in the diagnosis and monitoring of diseases such as HIV and certain types of cancers.

Pathology laboratories segment is poised to generate notable revenues over the forecast period, favored by the expertise in conducting comprehensive and precise diagnostic tests. The accessibility of specialized equipment and skilled professionals in these laboratories ensures the accuracy and reliability of blood screening results. Additionally, the increasing trend toward preventive healthcare and routine health check-ups enhances the demand for blood screening services provided by pathology laboratories.

Asia Pacific blood screening industry size is anticipated to grow at a significant pace over 2024-2032, favored by the region's growing population. The commitment towards enhancing healthcare infrastructure and the adoption of advanced medical technologies contribute to the wider usage of blood screening in preventive healthcare practices. As governments and healthcare providers increasingly focus on addressing public health challenges, the blood screening market experiences robust growth in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & working
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global blood screening market 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Product trends
  • 2.1.4 Technology trends
  • 2.1.5 End-use trends

Chapter 3 Blood Screening Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of infectious diseases
    • 3.2.1.2 Advancements in blood screening technology
    • 3.2.1.3 Growing blood transfusion procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of advanced technologies
    • 3.2.2.2 Limited access to trained professionals
• 3.3 Growth potential analysis
  • 3.3.1 By product
  • 3.3.2 By technology
  • 3.3.3 By end-use
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Technological landscape
• 3.7 Pricing analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis, 2023
• 4.3 Company market share analysis, 2023
• 4.4 Competitive analysis of major market players, 2023
• 4.5 Competitive positioning matrix, 2023
• 4.6 Strategy dashboard, 2023

Chapter 5 Blood Screening Market Size and Forecast, By Product, 2018-2032 (USD Million)

• 5.1 Key trends, by product
• 5.2 Reagents & kits
  • 5.2.1 NAT reagents & kits
    • 5.2.1.1 Enzymes & polymerases
    • 5.2.1.2 Standards & controls
    • 5.2.1.3 Probes & primers
    • 5.2.1.4 Buffer, nucleotides, and solutions
    • 5.2.1.5 Labelling & detection reagents
  • 5.2.2 ELISA
    • 5.2.2.1 Immunosorbents
    • 5.2.2.2 Controls
    • 5.2.2.3 Conjugates
    • 5.2.2.4 Substrates
    • 5.2.2.5 Sample diluents & wash solutions
  • 5.2.3 Other reagents & kits
• 5.3 Instruments

Chapter 6 Blood Screening Market Size and Forecast, By Technology, 2018-2032 (USD Million)

• 6.1 Key trends, by technology
• 6.2 Nucleic acid test
  • 6.2.1 Transcription-mediated amplification
  • 6.2.2 Real-time PCR
• 6.3 Serology/immunoassays
  • 6.3.1 Chemiluminescence immunoassay
  • 6.3.2 Fluoresecent immunoassays
  • 6.3.3 Colorimeter immunoassays/ELISA
• 6.4 Rapid test
• 6.5 Western blot assays
• 6.6 Next generation sequencing

Chapter 7 Blood Screening Market Size and Forecast, By End-use, 2018-2032 (USD Million)

• 7.1 Key trends, by end-use
• 7.2 Hospitals
• 7.3 Blood banks
• 7.4 Pathology laboratories

Chapter 8 Blood Screening Market Size and Forecast, By Region, 2018-2032 (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 F. Hoffmann-La Roche Ltd.
• 9.3 Grifols, S.A.
• 9.4 Hologic, Inc.
• 9.5 QIAGEN N.V.
• 9.6 Becton, Dickinson and Company
• 9.7 Bio-Rad Laboratories, Inc.
• 9.8 Siemens Healthineers AG
• 9.9 Thermo Fisher Scientific, Inc.
• 9.10 SOFINA s.a (Biomerieux)
• 9.11 Danaher Corporation
• 9.12 Ortho-Clinical Diagnostics, Inc.
• 9.13 DiaSorin S.p.A.